Five Prime Therapeutics, Inc. and Pfizer Inc. (NYSE:PFE) today announced the initiation of a worldwide collaborative research and license agreement. The collaboration will focus on the discovery of antibody targets and novel therapeutic protein products to treat certain areas of cancer and diabetes. Under the collaboration, FivePrime will screen its comprehensive protein library in both cell-based assays and primary in vivo screens directed toward finding potential therapeutic protein products and antibody targets.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments